Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Frozen FluMist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | FluMist |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Frozen FluMist® | BIOLOGICAL | Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL. |
| Placebo | OTHER | - |
Inclusion Criteria: * Male or female, 18 to 49 years of age (not yet reached their 50th birthday) at the time of study vaccination * Healthy by medical history and health assessment * Sexually active females, unless surgically sterile or at least 1 year post-menopausal, must have used an effective ...
Frozen FluMist is an investigational monoclonal antibody being studied for use in healthy adults. It is currently in Phase 2 clinical development. The drug is being evaluated for safety in a clinical trial involving healthy volunteers aged 18 years and older.
Frozen FluMist is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety of this investigational drug in healthy adult participants.
Frozen FluMist is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a Phase 2 clinical trial to evaluate its safety in healthy adults.
Frozen FluMist is being studied in a Phase 2 clinical trial with the identifier NCT00480155. This completed trial, titled 'A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults,' enrolled 300 participants in the United States. The study was randomized, double-blind, and placebo-controlled.
Frozen FluMist is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The drug has completed a Phase 2 clinical trial evaluating its safety in healthy adults, but it has not yet received regulatory approval for any use.